公开(公告)号：US20210088520A1

公开(公告)日：2021-03-25

申请号：US17009126

申请日：2020-09-01

申请人： Agios Pharmaceuticals, Inc.

发明人： Yaguang Si ,  Marie C. Keenan

IPC分类号： G01N33/574 ,  A61K31/47 ,  A61K31/519 ,  C12Q1/6886 ,  A61K31/42 ,  A61K31/167 ,  A61K31/44 ,  A61K31/381 ,  A61K31/4418 ,  A61K31/341 ,  A61K31/277 ,  A61P35/00

摘要： The present invention provides diagnostic and prognostic methods for predicting the effectiveness of treatment of a cancer patient with a DHODH inhibitor or an antimetabolite. Methods are provided for predicting the sensitivity of tumor cell growth to inhibition by a DHODH inhibitor or an antimetabolite, comprising assessing whether the tumor cell comprises a mutant IDH gene or protein whereby cells that comprise a mutant IDH gene or protein are sensitive to inhibition by DHODH inhibitors and antimetabolites.

公开(公告)号：US20190025313A1

公开(公告)日：2019-01-24

申请号：US16066984

申请日：2016-12-29

申请人： Agios Pharmaceuticals, Inc.

发明人： Yaguang Si ,  Marie C. Keenan

IPC分类号： G01N33/574 ,  A61P35/00 ,  C12Q1/6886 ,  A61K31/519 ,  A61K31/47

摘要： The present invention provides diagnostic and prognostic methods for predicting the effectiveness of treatment of a cancer patient with a DHODH inhibitor or an antimetabolite. Methods are provided for predicting the sensitivity of tumor cell growth to inhibition by a DHODH inhibitor or an antimetabolite, comprising assessing whether the tumor cell comprises a mutant IDH gene or protein whereby cells that comprise a mutant IDH gene or protein are sensitive to inhibition by DHODH inhibitors and antimetabolites.